Completed PHASE2 INTERVENTIONAL 2-arm NCT01109264

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Interventions Bendamustine hydrochloride injection Chlorambucil

Updated 5 times since 2017 Last updated: Aug 21, 2013 Started: Mar 31, 2010 Primary completion: Jun 30, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01109264, this PHASE2 trial focuses on Chronic Lymphocytic Leukemia and remains completed. Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Data source: Jiangsu Simcere Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China